Gilead Sciences, Inc. (DB:GIS) Stock Price & Quote Analysis

GIS Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GIS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	2/6

Rewards

Trading at 50.7% below our estimate of its fair value

Earnings are forecast to grow 9.29% per year

Risk Analysis

Has a high level of debt

Dividend of 3.59% is not well covered

Large one-off items impacting financial results

Profit margins (12.3%) are lower than last year (26.9%)

My Notes

New

Notes are coming soon

Gilead Sciences, Inc. Competitors

Formycon

XTRA:FYB

€1.2b

MERCK Kommanditgesellschaft auf Aktien

XTRA:MRK

€80.0b

Bayer

XTRA:BAYN

€55.8b

CSL

ASX:CSL

AU$146.9b

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share Price	US$74.35
52 Week High	US$84.73
52 Week Low	US$52.23
Beta	0.43
1 Month Change	-8.45%
3 Month Change	-7.90%
1 Year Change	29.17%
3 Year Change	19.92%
5 Year Change	12.82%
Change since IPO	446.99%

Recent updates

Shareholder Returns

	GIS	DE Biotechs	DE Market
7D	-2.6%	-2.4%	3.4%
1Y	29.2%	6.9%	-8.2%

Return vs Industry: GIS exceeded the German Biotechs industry which returned 4.5% over the past year.

Return vs Market: GIS exceeded the German Market which returned -11.7% over the past year.

Price Volatility

Is GIS's price volatile compared to industry and market?
GIS volatility
GIS Average Weekly Movement	3.1%
Biotechs Industry Average Movement	5.6%
Market Average Movement	5.2%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: GIS is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GIS's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1987	14,400	Dan O'Day	https://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GIS fundamental statistics
Market Cap	€96.56b
Earnings (TTM)	€3.06b
Revenue (TTM)	€24.87b

30.6x

P/E Ratio

3.8x

P/S Ratio

Is GIS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
GIS income statement (TTM)
Revenue	US$27.14b
Cost of Revenue	US$5.64b
Gross Profit	US$21.50b
Other Expenses	US$18.16b
Earnings	US$3.33b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	2.66
Gross Margin	79.22%
Net Profit Margin	12.29%
Debt/Equity Ratio	119.8%

How did GIS perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

109%

Payout Ratio

GIS Stock Overview

Rewards

Risk Analysis

Gilead Sciences, Inc. Competitors

XTRA:FYB

€1.2b

XTRA:MRK

€80.0b

XTRA:BAYN

€55.8b

ASX:CSL

AU$146.9b

Price History & Performance

Recent News & Updates

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Gilead Sciences, Inc. to Report Q4, 2022 Results on Feb 02, 2023

Gilead Sciences, Inc. Announces European Medicines Agency Validates Marketing Authorization Application for Trodelvy(R) (Sacituzumab Govitecan-Hziy) for Pre-Treated Hr+/Her2- Metastatic Breast Cancer

Gilead Sciences, Inc.'s Sunlenca(R) (Lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living with Multi-Drug Resistant HIV

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients

Kite's Tecartus Car T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response

Recent updates

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Gilead Sciences, Inc. to Report Q4, 2022 Results on Feb 02, 2023

Gilead Sciences, Inc. Announces European Medicines Agency Validates Marketing Authorization Application for Trodelvy(R) (Sacituzumab Govitecan-Hziy) for Pre-Treated Hr+/Her2- Metastatic Breast Cancer

Gilead Sciences, Inc.'s Sunlenca(R) (Lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living with Multi-Drug Resistant HIV

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients

Kite's Tecartus Car T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response

Upcoming dividend of US$0.73 per share

Gilead Sciences, Inc. Announces New Data From Post-Hoc Analysis from Phase 3 TROPiCS-02 Study

Gilead Sciences, Inc Announces U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients

Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis At the Liver Meeting® 2022

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Third quarter 2022 earnings released: EPS: US$1.43 (vs US$2.06 in 3Q 2021)

Gilead Sciences, Inc. Revises Earnings Guidance for the Full-Year of 2022

Gilead Sciences, Inc. Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living with HIV with A Range of Comorbidities

Gilead Presents Real-World and Long-Term Data from HIV Research Programs At HIV Glasgow 2022

Gilead Sciences, Inc. to Report Q3, 2022 Results on Oct 27, 2022

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Hiv-Positive Consumer Joins Lawsuit Against Gilead Sciences, Inc. over Price Gouging

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of MiroBio Ltd.

Gilead Sciences, Inc. Announces Committee for Medicinal Products for Human Use of European Medicines Agency Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for Treatment of Pediatric Patients with COVID-19

Gilead Sciences, Inc. Announces the Positive Overall Survival Results from the Phase 3 TROPiCS-02 Study Evaluating Trodelvy

Upcoming dividend of US$0.73 per share

Gilead Sciences, Inc. Announces New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy Regardless of Their HER2 Status

Gilead Sciences, Inc. Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option

Gilead Sciences, Inc. Announces Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/Her2- Metastatic Breast Cancer Patients in the Tropics-02 Study

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into a definitive agreement to acquire MiroBio Ltd from SR One Capital Management, LP, Samsara BioCapital LLC, Oxford Science Enterprises, OrbiMed Advisors LLC, Medicxi Ventures (UK) LLP and Advent Life Sciences LLP for approximately $410 million.

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$1.21 in 2Q 2021)

Gilead Sciences, Inc. Declares Quarterly Cash Dividend for the Third Quarter of 2022, Payable on September 29, 2022

Gilead Sciences, Inc. Announces Executive Changes

Gilead Sciences, Inc. Announces Results Reinforcing Biktarvy

Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Gilead Sciences, Inc.'s Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients with Covid-19

Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel

GlaxoSmithKline plc (LSE:GSK) completed the acquisition of Sierra Oncology, Inc. (NasdaqGM:SRRA) from Frazier Healthcare VI, L.P., Frazier Life Sciences VIII, L.P., Frazier Life Sciences Public Fund, L.P., all managed by Frazier Management, L.L.C., and others.

Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opinion for People with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces Week 48 Results from the Pivotal Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepcludex® (Bulevirtide) for the Treatment of Chronic Hepatitis Delta Virus (Hdv) Infection

Gilead Sciences New Data Highlights People Living with Hiv Who Are Virally Suppressed Experience Similar Health-Related Quality of Life as General Population

Upcoming dividend of US$0.73 per share

Final Data from Phase 3 Ascent Study Demonstrates Trodelvy Extends Overall Survival over Chemotherapy in Second-Line Metastatic TNBC

Gilead Sciences, Inc. Announces Positive Results from the Primary Analysis of the Phase 3 TROPiCS-02 Study of Trodelvy®

Gilead Sciences, Inc. Announces Executive Changes

U.S. Food and Drug Administration Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV

First quarter 2022 earnings released: EPS: US$0.015 (vs US$1.38 in 1Q 2021)

Gilead Sciences Announces Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

Gilead Sciences, Inc. Announces Findings from Two Studies, Which Provide Further Insights on the Use of Veklury® (Remdesivir) for the Treatment of Hospitalized and Non-Hospitalized Patients with COVID-19

Gilead Sciences, Inc. to Report Q1, 2022 Results on Apr 28, 2022

U.S. Food and Drug Administration Lifts Partial Clinical Hold on Gilead Sciences, Inc.'s MDS and AML Magrolimab Studies

U.S. Food and Drug Administration Lifts Partial Clinical Hold on Gilead Sciences, Inc's MDS and AML Magrolimab Studies

The Maryknoll Sisters of St. Dominic, Inc Urges Shareholders of Gilead Sciences Inc to Support Its Shareholders Proposal

Kite, a Gilead Company Announces Yescarta Receives U.S. Food and Drug Administration Approval as First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Upcoming dividend of US$0.73 per share

Gilead Sciences, Inc. Announces New One-Year Results from the Ongoing Phase 2/3 CAPELLA Trial Evaluating Lenacapavir

Gilead Sciences, Inc. Announces Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022

Gilead Sciences, Inc. Announces Veklury (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies

GlaxoSmithKline plc Announces Settlement between ViiV Healthcare and Gilead Sciences, Inc

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Gilead Sciences, Inc. Reaches Settlement with ViiV Healthcare Company, ViiV Healthcare UK (No.3) Limited, ViiV Healthcare UK Limited, Shionogi & Co., Ltd. and GlaxoSmithKline Mercury Limited

U.S. FDA Approves New Label Update for Car T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome

Gilead Sciences Inc. Announces U.S. Food and Drug Administration Place Partial Clinical Hold for Studies Evaluating Magrolimab in Combination with Azacitidine